Our respondents identified several barriers to FMT use. As
confirmed by our study findings, reimbursement of the costs
associated with screening of the stool donor and the logistics of
sample preparation and delivery have been significant barriers [16].
However, the recent approval of CPT code 44705 (G-code 0455)
promises to ameliorate components of these problems, and to
allow at least a partial recovery of the costs associated with FMT
[17]. Only rarely did respondents cite patient refusal as a barrier to
FMT, in keeping with a recent survey indicating that most patients
would consider this alternative treatment for RCDI [16].